XML 64 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2023
Feb. 28, 2019
Jun. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation Of Revenue [Line Items]            
Revenue from collaboration agreement       $ 178,957,000 $ 170,276,000 $ 185,308,000
Immune Medicine Service Revenue            
Disaggregation Of Revenue [Line Items]            
Revenue from collaboration agreement       13,500,000 42,600,000 62,800,000
Medicare Reimbursements            
Disaggregation Of Revenue [Line Items]            
Revenue from collaboration agreement       6,500,000 5,600,000 5,200,000
Medicare Reimbursements | Immune Medicine Service Revenue            
Disaggregation Of Revenue [Line Items]            
Revenue from collaboration agreement       1,200,000 $ 600,000 $ 700,000
MRD Development Agreements | Maximum            
Disaggregation Of Revenue [Line Items]            
Additional milestone payment receivable       418,500,000    
Genentech Collaboration Agreement            
Disaggregation Of Revenue [Line Items]            
Revenue from collaboration agreement     $ 7,700,000      
Non-refundable upfront payments received   $ 300,000,000   300,000,000    
Additional transaction price of regulatory milestone $ 10,000,000          
Expected revenue through milestone payments       $ 1,800,000,000    
Genentech Collaboration Agreement | Regulatory Milestones            
Disaggregation Of Revenue [Line Items]            
Additional transaction price of regulatory milestone $ 10,000,000          
Genentech Collaboration Agreement | Maximum            
Disaggregation Of Revenue [Line Items]            
Revenue recognition expected period       10 years    
Genentech Collaboration Agreement | Maximum | Regulatory Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments       $ 65,000,000    
Genentech Collaboration Agreement | Maximum | Development Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments       300,000,000    
Genentech Collaboration Agreement | Maximum | Commercial Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments       $ 1,430,000,000    
Genentech Collaboration Agreement | Minimum            
Disaggregation Of Revenue [Line Items]            
Revenue recognition expected period       9 years